Protein kinase Cδ constrains the S‐pathway to phrenic motor facilitation elicited by spinal 5‐HT7 receptors or severe acute intermittent hypoxia. (2nd December 2018)

• Record Type: Journal Article
• Authors: Perim, Raphael R.; Fields, Daryl P.; Mitchell, Gordon S.
• Is Part Of: Journal of physiology. Volume 597:Number 2(2019)
• Page Start: 481
• Page End: 498
• Publication Date: 2018-12-02
• Subjects: respiratory motor plasticity -- phrenic motor facilitation -- cross‐talk inhibition; Physiology -- Periodicals; 612.005
• DOI: 10.1113/JP276731
• Languages: English
• ISSNs: 0022-3751

Abstract

Abstract : Key points: Concurrent 5‐HT2A (Q pathway) and 5‐HT7 (S pathway) serotonin receptor activation cancels phrenic motor facilitation due to mutual cross‐talk inhibition. Spinal protein kinase Cδ (PKCδ) or protein kinase A inhibition restores phrenic motor facilitation with concurrent Q and S pathway activation, demonstrating a key role for these kinases in cross‐talk inhibition. Spinal PKCδ inhibition enhances adenosine‐dependent severe acute intermittent hypoxia‐induced phrenic long‐term facilitation (S pathway), consistent with relief of cross‐talk inhibition. Abstract: Intermittent spinal serotonin receptor activation elicits long‐lasting phrenic motor facilitation (pMF), a form of respiratory motor plasticity. When activated alone, spinal Gq protein‐coupled serotonin 2A receptors (5‐HT2A ) initiate pMF by a mechanism that requires ERK‐MAP kinase signalling and new BDNF protein synthesis (Q pathway). Spinal Gs protein‐coupled serotonin 7 (5‐HT7 ) and adenosine 2A (A2A ) receptor activation also elicits pMF, but via distinct mechanisms (S pathway) that require Akt signalling and new TrkB protein synthesis. Although studies have shown inhibitory cross‐talk interactions between these competing pathways, the underlying cellular mechanisms are unknown. We propose the following hypotheses: (1) concurrent 5‐HT2A and 5‐HT7 activation undermines pMF; (2) protein kinase A (PKA) and (3) NADPH oxidase mediate inhibitory interactions between Q (5‐HT2A ) and S (5‐HT7 ) pathways. Selective 5‐HT2A (DOI hydrochloride) and 5HT7 (AS‐19) agonists were administered intrathecally at C4 (three injections, 5‐min intervals) in anaesthetized, vagotomized and ventilated male rats. With either spinal 5‐HT2A or 5‐HT7 activation alone, phrenic amplitude progressively increased (pMF). In contrast, concurrent 5‐HT2A and 5‐HT7 activation failed to elicit pMF. The 5‐HT2A ‐induced Q pathway was restored by inhibiting PKA activity (Rp‐8‐Br‐cAMPS). NADPH oxidase inhibition did not prevent cross‐talk inhibition. Therefore, we investigated alternative mechanisms to explain Q to S pathway inhibition. Spinal protein kinase C (PKC) inhibition with Gö6983 or PKCδ peptide inhibitor restored the 5‐HT7 ‐induced S pathway to pMF, revealing PKCδ as the relevant isoform. Spinal PKCδ inhibition enhanced the S pathway‐dependent form of pMF elicited by severe acute intermittent hypoxia. We suggest that powerful constraints between 5‐HT2A and 5‐HT7 or A2A receptor‐induced pMF are mediated by PKCδ and PKA, respectively. Key points: Concurrent 5‐HT2A (Q pathway) and 5‐HT7 (S pathway) serotonin receptor activation cancels phrenic motor facilitation due to mutual cross‐talk inhibition. Spinal protein kinase Cδ (PKCδ) or protein kinase A inhibition restores phrenic motor facilitation with concurrent Q and S pathway activation, demonstrating a key role for these kinases in cross‐talk inhibition. Spinal PKCδ inhibition enhances adenosine‐dependent severe acute intermittent hypoxia‐induced phrenic long‐term facilitation (S pathway), consistent with relief of cross‐talk inhibition.